

Cu-67 ISOTOPE PRODUCTION *(overview)*

Based on the 2017' ST Review presentation by G. Kharashvili, July 2017

**Hari Areti¹, Pavel Degtiarenko², Sundaresan
Gobalakrishnan³, Joe Gubeli¹, Andrew Hutton¹,
Kevin Jordan¹, George Kharashvili²,
George Neil¹, Doug Wells⁴, Jamal Zweit³**

¹ Jefferson Lab Accelerator Division / CASA

² Jefferson Lab Radiation Control

³ Virginia Commonwealth University

⁴ New Mexico Tech

Isotope Kick-off mtg, Aug 2018

^{67}Cu for Targeted Radiotherapy

- **Theranostic** radionuclide
 - 141 keV mean energy β^- for therapy (has the range in tissue of the order of a cell diameter)
 - 185 keV energy photons for SPECT imaging
 - Can be paired with ^{64}Cu for PET imaging
- Near-ideal half-life of 61.8 hours
 - Convenient for production, transportation, and delivery to patient
 - Same order as biological half-life of copper and zinc (^{67}Cu decays to stable ^{67}Zn)
- Favorable biochemistry – approved for human trials
 - Not a bone or an organ seeker
 - Not acutely toxic – both Cu and Zn are essential trace nutrients


⁶⁷Cu Properties

- $T_{1/2} = 61.83$ h
- **Therapeutic:**
 - β^- ranges in tissue are of the order of a cell diameter

Endpoint Energy (keV)	Yield (%)
183.5	1.1
392.4	57
483.7	22
577	20

- **Diagnostic**
 - 185 keV photon with 48.7% yield
 - 93.3 keV photon with 16.1% yield

How is ^{67}Cu Produced?



- $^{68}\text{Zn}(p, 2p)^{67}\text{Cu}$
- $^{70}\text{Zn}(p, \alpha)^{67}\text{Cu}$
- $^{67}\text{Zn}(n, p)^{67}\text{Cu}$

- $^{68}\text{Zn}(\gamma, p)^{67}\text{Cu}$
- $^{71}\text{Ga}(\gamma, \alpha)^{67}\text{Cu}$
 - 2017 JSA Patent Submitted

Demand and Availability of ^{67}Cu

- Historical lack of an adequate and reliable supply has impeded the development of ^{67}Cu applications
- By some estimates (based on treating a half of all new Non-Hodgkin Lymphomas) there is a potential US demand of ~ 12000 Ci / year

Smith, Bowers, Ehst, “The production, separation, and use of ^{67}Cu for radioimmunotherapy: A review”, *Applied Radiation and Isotopes* 70 (2012) 2377–2383

- ^{67}Cu is currently produced:
 - Brookhaven National Laboratory: Proton irradiation of zinc, produced periodically, $\sim 60\%$ of activity upon delivery is composed of ^{64}Cu
 - Idaho Accelerator Center: Photoproduction in zinc up to 10s of mCi / week, not intended for human use
- **Higher specific activities and improved radiological purity are desired**


Photoproduction of ^{67}Cu in Gallium via $^{71}\text{Ga}(\gamma, \alpha)^{67}\text{Cu}$ (1)

- Gallium has favorable properties for high power targets
 - ✓ Low melting point of 30 °C
 - ✓ High boiling point of 2204 °C
 - ✓ Low vapor pressure
 - ✗ Corrosive to metals except tungsten and tantalum
- A 50 kW irradiation of optimal Ga target will produce *
 - 100s mCi of ^{67}Cu per week in natural gallium
 - > 1 Ci/week in ^{71}Ga (40% of natural Ga)
 - Typical medical dose of ^{67}Cu – order of 10 mCi

* Yields are calculated using FLUKA and scaled with data

Photoproduction of ^{67}Cu in Gallium via $^{71}\text{Ga}(\gamma,\alpha)^{67}\text{Cu}$ (2)


- Modest cross-section of $^{71}\text{Ga}(\gamma,\alpha)^{67}\text{Cu}$ reaction can be compensated by high beam power and a thick target



Koning *et al.*
"TENDL-2015:
TALYS-based
evaluated
nuclear data
library"

https://tendl.web.psi.ch/tendl_2015/tendl2015.html

Photoproduction of ^{67}Cu in Gallium via $^{71}\text{Ga}(\gamma, \alpha)^{67}\text{Cu}$ (3)




Overall Objectives and First Steps

- The overall objective is to integrate
 - Production
 - Chemical Separation
 - Delivery
- First (opportunistic) steps
 - Confirm ^{67}Cu production in gallium
 - Chemically separate ^{67}Cu from gallium
 - Investigate ^{67}Cu delivery mechanisms

First Opportunistic Irradiation Test

- Irradiation of Ga and Zn targets during beam studies in CEBAF injector:
 - 18.5 MeV (to avoid interference from ^{67}Ga), 2.5 μA , 1 h
 - $\sim 0.1 \mu\text{Ci}$ ^{67}Cu detected in each




Chemical Separation Test

- Chemical separation test at Virginia Commonwealth University (VCU)
 - 1 mCi of ^{67}Cu was obtained from the National Isotope Development Center, shipped from BNL to VCU
 - The sample was dissolved in HCl and added to Gallium Chloride in solution
 - Separation by liquid-liquid extraction and column chromatography recovered ~95% of the radioactive copper after a single pass

Second Opportunistic Irradiation Test (1)

- During 2017 beam studies of 4K operation in CEBAF injector a parasitic isotope irradiation opportunity was realized
- 85 g gallium target irradiated for several hours at ~1 kW (18.65 MeV, 50 μ A) with the intent to chemically separate ^{67}Cu




Second Opportunistic Irradiation Test (2)

- Due to failure of monitoring instrumentation, run was terminated earlier than anticipated
- ~130 μCi ^{67}Cu was produced, ~70 μCi was available at the time of sample retrieval (expected to produce ~500 μCi)
- Due to transportation and communication issues did not proceed with chemical separation
- The two low energy irradiation tests showed reasonable agreement with the model predictions
 - FLUKA (our primary tool for activation calculations) appears to overestimate ^{67}Cu yields in Ga by approximately a factor of 2 at 18.5 MeV maximum bremsstrahlung energy

Summary and Proposed Future Work

- ^{67}Cu production via the $^{71}\text{Ga}(\gamma, \alpha)^{67}\text{Cu}$ reaction at LERF:
Production of **high specific activity theranostic** isotope using **high power electron accelerator**
 - ✓ Measured photoproduction of ^{67}Cu at low energies (< 20 MeV) with no ^{64}Cu content
 - ✓ Chemically separated ^{67}Cu from Ga (obtained from BNL, then dissolved in Ga)
 - Proposed future work
 - Complete smooth integration of photoproduction and chemical separation
 - Produce ^{67}Cu in Ga target at optimal electron beam energies (> 30 MeV)
 - Develop high power target system

NSAC Isotopes Recommendations on Isotope R&D



- “Continue support for R&D on the production of **alpha-emitting** radioisotopes”
- “Support R&D into the production of **high specific activity theranostic** radioisotopes”
- “Continue support for R&D on the **use of electron accelerators** for isotope production”
- “Support R&D on the development of **irradiation materials for targets** that will be exposed to **extreme environments** to take full advantage of the current suite of accelerator and reactor irradiation facilities”